Skip to search formSkip to main contentSkip to account menu

bosutinib

Known as: 4-Anilino-3-quinolinecarbonitrile, 4-Anilinobenzo(g)quinoline-3-carbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile 
A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike… 
National Institutes of Health

Related topics

Related topics

13 relations

Broader (3)

Aniline CompoundsNitrilesQuinolines

Narrower (3)

BosulifBosutinib monohydrateSKI-606
Inhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisReceptor Protein-Tyrosine Kinases

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Current approach to the treatment of chronic myeloid leukaemia.
Review
2015
Review
2015
Optimal management for pediatric chronic myeloid leukemia
Chronic myeloid leukemia (CML) is rare among childhood leukemias. Its incidence increases with age, from 0.09/100 000 at ≤15… 
Review
2013
Review
2013
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or…
On pages 4568, 4572, 4574, and 4576 of the 27 October 2011 issue, there are errors in the text. On page 4568 in the “Study design… 
2013
2013
PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation
Highly Cited
2011
Highly Cited
2011
Identification of a Src Tyrosine Kinase/SIAH2 E3 Ubiquitin Ligase Pathway That Regulates C/EBPδ Expression and Contributes to Transformation of Breast Tumor Cells
ABSTRACT The transcription factor CCAAT/enhancer-binding protein delta (C/EBPδ, CEBPD) is a tumor suppressor that is… 
Highly Cited
2010
Highly Cited
2010
SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis
In the current study, we have examined the efficacy of a Src/Abl kinase inhibitor SKI-606 (Bosutinib) for its effect on prostate… 
2010
2010
An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Abstract 208 Bosutinib is an orally bioavailable dual Src/Abl tyrosine kinase inhibitor (TKI), with minimal inhibitory activity… 
Review
2010
Review
2010
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells
Resistance to the BCR-ABL tyrosine kinase inhibitor imatinib poses a pressing challenge in treating chronic myeloid leukemia (CML… 
2009
2009
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
Recently, Src tyrosine kinase has emerged as an attractive target for anticancer therapy, and Src is overexpressed in pancreatic… 
2009
2009
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells
Unbalanced histone deacetylase (HDAC) hyperactivity is a common feature of tumor cells. Inhibition of HDAC activity is often… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)